Literature DB >> 11114235

Effects of the myosin inhibitor 2,3-butanedione monoxime (BDM) on cell shape, locomotion and fluid pinocytosis in human polymorphonuclear leucocytes.

N Urwyler1, P Eggli, H U Keller.   

Abstract

We investigated the role of myosin in polymorphonuclear leucocyte (PMN) shape changes, locomotion, and fluid pinocytosis using the myosin inhibitor 2,3 butanedione monoxime (BDM). Treatment of resting spherical PMNs with BDM produced spheroid cells showing small continuous shape changes (IC(50)=15.5 m m BDM) and occasionally small blebs. Cell polarity, as induced by the chemotactic peptide fNLPNTL or by colchicine, and locomotion were completely suppressed (IC(50)=8.4 to 10 m m). Suppression of fNLPNTL- or colchicine-induced cell polarity produced spheroid cells, suppression of PMA-induced shape changes and fluid pinocytosis produced non-motile spherical cells (IC(50)=25 to 30 m m BDM). BDM suppressed formation of lamellipodia but not formation of blebs. Suppression of microvilli by BDM as observed in resting spherical cells was partially antagonized by PMA. The results suggest that myosin is involved in stabilizing the shape of resting spherical cells, including microvilli, and that myosin is required for cell polarity, locomotion, fluid pinocytosis and for formation of lamellipodia, but not for formation of blebs. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114235     DOI: 10.1006/cbir.2000.0579

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  2 in total

1.  Development of a wound dressing targeting neutrophil function.

Authors:  Håkan Nygren; Per Malmberg; Herman Sahlin
Journal:  World J Surg       Date:  2004-02-17       Impact factor: 3.352

2.  Intercellular transfer and supramolecular organization of human leukocyte antigen C at inhibitory natural killer cell immune synapses.

Authors:  L M Carlin; K Eleme; F E McCann; D M Davis
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.